Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYRO3 | Q06418 | 11/20 | 0.39 |
| ▸ | AXL | P30530 | 3/20 | 0.39 |
| ▸ | MERTK | Q12866 | 6/20 | 0.39 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.38 |
| ▸ | NEK7 | Q8TDX7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL60061 | 0.87 | BTK (0.43) | TYRO3AXLMERTKACVRL1NEK7 | |
| SCHEMBL841952 | 0.81 | RET (0.44) | TYRO3AXLMERTK | |
| SCHEMBL842074 | 0.81 | TYRO3 (0.49) | TYRO3AXLMERTK | |
| SCHEMBL58989 | 0.79 | RET (0.43) | TYRO3AXL | |
| SCHEMBL5036616 | 0.76 | RET (0.52) | TYRO3AXLMERTKACVRL1 | |
| SCHEMBL27747228 | 0.76 | BTK (0.46) | TYRO3AXLMERTKACVRL1 | |
| SCHEMBL841528 | 0.75 | FLT3 (0.43) | MERTKACVRL1NEK7 | |
| SCHEMBL841527 | 0.75 | FLT3 (0.43) | MERTKACVRL1NEK7 | |
| SCHEMBL59006 | 0.74 | RET (0.54) | TYRO3AXLMERTKACVRL1NEK7 | |
| SCHEMBL5031566 | 0.74 | FGFR1 (0.51) | TYRO3AXLMERTKACVRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100063038-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | BAYER HEALTHCARE LLC | 2010-03-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063038-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | CDK4, CDKL4, MKI67 | TYRO3 2612/4885AXL 2194/4885MERTK 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.